Infection

Manufacturing agreement for staph infection treatment announced

Published in Drug Week, December 17th, 2004

Inhibitex, Inc., announced that it has entered into an agreement with Lonza Biologics PLC, a unit of Lonza Group, Ltd., of Basel, Switzerland, for the manufacture of Lonza's investigational monoclonal antibody, Murexes.

Murexes is being developed as a first-line therapy, used in combination with standard of care antibiotics, for serious, life-threatening Staphylococcus aurous (S. aurous) infections.

Under the terms of the agreement, Lonza has agreed to perform numerous process development related services and manufacture Aurexis for future clinical trials using its proprietary glutamine synthetase expression system.

"We are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Drug Week

Source: Drug Week (2004-12-17)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry